Manjusha Gaglani Selected Research

Messenger RNA (mRNA)

3/2024	Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.
1/2024	Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
8/2023	Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5-11 Years in a Multisite Prospective Cohort Study, September 2021-September 2022.
5/2023	Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
4/2023	Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023.
3/2023	Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
1/2023	Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
1/2023	Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
1/2023	Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
1/2023	Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manjusha Gaglani Research Topics

Disease

78	COVID-19 04/2024 - 01/2021
75	Human Influenza (Influenza) 04/2024 - 02/2014
36	Infections 03/2024 - 02/2014
3	Cough 01/2023 - 05/2016
3	Breakthrough Infections 01/2022 - 01/2021
2	Respiratory Insufficiency (Respiratory Failure) 12/2023 - 03/2022
2	Critical Illness (Critically Ill) 05/2023 - 01/2023
2	Fever (Fevers) 10/2022 - 01/2018
2	Disease Progression 10/2022 - 11/2021
2	Pneumonia (Pneumonitis) 01/2022 - 01/2018
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020 - 01/2018
1	Mental Disorders (Mental Disorder) 03/2024
1	Hypoxia (Hypoxemia) 12/2023
1	Renal Insufficiency (Renal Failure) 12/2023
1	Vision Disorders (Hemeralopia) 11/2023
1	Chills 10/2022
1	Hepatitis D 10/2022
1	Coinfection 10/2022
1	Thrombocytopenia (Thrombopenia) 04/2022
1	Thrombosis (Thrombus) 04/2022
1	Asymptomatic Infections 08/2021
1	Drug-Related Side Effects and Adverse Reactions 12/2020
1	Frailty 01/2019
1	Pharyngitis (Sore Throat) 01/2018
1	Sinusitis 01/2018
1	Bronchitis 01/2018
1	Herpesviridae Infections (Herpesvirus Infection) 02/2014
1	Measles 10/2011
1	Mumps 10/2011
1	Chickenpox 10/2011
1	Rubella (German Measles) 10/2011

Drug/Important Bio-Agent (IBA)

103	VaccinesIBA 03/2024 - 10/2011
46	Influenza Vaccines (Influenza Vaccine)FDA Link 02/2024 - 02/2014
38	mRNA VaccinesIBA 02/2024 - 01/2021
36	Messenger RNA (mRNA)IBA 03/2024 - 01/2021
36	COVID-19 VaccinesIBA 03/2024 - 04/2021
11	BNT162 VaccineIBA 01/2023 - 01/2021
10	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2023 - 02/2014
7	N-(2-cyanoethylene)urea (BA 1)IBA 09/2023 - 07/2022
6	Antiviral Agents (Antivirals)IBA 03/2022 - 02/2014
5	Combined VaccinesIBA 01/2024 - 01/2021
5	AntibodiesIBA 12/2023 - 01/2015
5	2019-nCoV Vaccine mRNA-1273IBA 03/2022 - 01/2021
5	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 01/2015
4	Neutralizing AntibodiesIBA 09/2023 - 01/2022
4	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 07/2022
3	Proteins (Proteins, Gene)FDA Link 11/2023 - 10/2022
3	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 09/2014
2	Oxygen (Dioxygen)IBA 12/2023 - 10/2023
2	Immunoglobulin G (IgG)IBA 11/2023 - 09/2021
2	Viral RNAIBA 11/2023 - 01/2021
2	AntigensIBA 09/2023 - 01/2023
2	Ad26COVS1IBA 10/2022 - 10/2021
2	Attenuated VaccinesIBA 01/2021 - 10/2017
2	Inactivated VaccinesIBA 01/2021 - 12/2018
2	Neuraminidase (Sialidase)IBA 09/2016 - 01/2015
1	Respiratory Syncytial Virus VaccinesIBA 04/2024
1	perfluorooctane sulfonic acidIBA 12/2023
1	perfluorooctanoic acidIBA 12/2023
1	perfluoro-n-nonanoic acidIBA 12/2023
1	perfluorohexanesulfonic acidIBA 12/2023
1	Nucleocapsid ProteinsIBA 11/2023
1	RNA (Ribonucleic Acid)IBA 11/2023
1	EpitopesIBA 09/2023
1	NucleoproteinsIBA 10/2022
1	COVID-19 vaccine booster shotIBA 04/2022
1	Stored Messenger RNAIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 12/2021
1	Nucleic AcidsIBA 11/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	CI 22IBA 01/2019
1	Hepatitis A Vaccines (Hepatitis A Vaccine)IBA 10/2011

Therapy/Procedure

21	Ambulatory Care (Outpatient Care) 03/2024 - 09/2014
7	Artificial Respiration (Mechanical Ventilation) 04/2024 - 11/2021
2	Therapeutics 10/2023 - 09/2014
1	Noninvasive Ventilation 10/2023
1	Cannula 10/2023
1	Critical Care (Surgical Intensive Care) 01/2022
1	Mechanical Ventilators (Ventilator) 12/2021
1	Length of Stay 12/2021